Related Experiment Video
Updated: Aug 6, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Structural and Energetic Determinants of Monobody Recognition of Oncogenic KRAS Variants
1Department of Physics and Astronomy, Wayne State University, Detroit, MI 48201, USA.
Abstract:
Monobodies are engineered binding proteins that recognize extended protein surfaces and offer advantages over small-molecule inhibitors for targeting challenging KRAS oncoproteins. Monobody 12D4 exhibits high affinity and selectivity for the oncogenic KRAS(G12D) mutant, but the molecular determinants governing its recognition and the basis for its mutant selectivity remain poorly understood. Here, we combined molecular dynamics simulations and energy calculations to characterize the interactions between monobody 12D4 and WT KRAS as well as four clinically relevant oncogenic variants (G12C, G12D, G12V, and G12R) in both GTP- and GDP-bound states. Our simulations revealed that 12D4 recognition depends on a conserved hydrophobic interaction network centered on the monobody FG loop (residues L77, F78, and W79). This network forms stable contacts with KARS Switch II and α3-helix. The energy calculations also showed that residue K75 of 12D4 formed a mutation-specific electrostatic interaction with KRAS G12D. This interaction contributed significantly to the affinity of 12D4 toward this mutant, whereas this interaction was absent in other variants. No monobody currently exists for targeting KRAS G12R in either nucleotide state, and no monobody selectively targets KRAS G12C and G12V in the GDP-bound inactive state. To address these, we performed computational redesign at residues 75. We identified mutations (K75Q, K75Y, and K75M) that enhanced predicted binding to G12C, G12R, and G12V variants through reorganization of interfacial contacts. Our work establishes a structural framework for understanding KRAS-monobody recognition and provides a rational foundation for engineering variant-selective monobodies with improved affinity toward previously untargetable KRAS mutants.
Insights
Engineered monobodies show promise for targeting KRAS oncoproteins. Computational redesign of monobody 12D4 enhances binding to previously untargetable KRAS variants, offering new therapeutic strategies.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- KRAS oncoproteins are challenging therapeutic targets.
- Monobodies offer advantages over small molecules for KRAS inhibition.
- Understanding monobody-KRAS interactions is crucial for drug development.
Purpose of the Study:
- To elucidate the molecular determinants of monobody 12D4 recognition of KRAS variants.
- To investigate the basis for monobody 12D4's selectivity towards KRAS(G12D).
- To computationally redesign monobodies for enhanced affinity against untargetable KRAS mutants.
Main Methods:
- Molecular dynamics (MD) simulations.
- Energy calculations.
- Computational protein redesign.
Main Results:
- Monobody 12D4 recognition involves a hydrophobic network interacting with KRAS Switch II and α3-helix.
- A mutation-specific electrostatic interaction between 12D4 (K75) and KRAS G12D significantly enhances binding affinity.
- Computational redesign identified mutations (K75Q, K75Y, K75M) improving predicted binding to KRAS G12C, G12R, and G12V.
Conclusions:
- A structural framework for KRAS-monobody recognition has been established.
- The study provides a rational basis for engineering variant-selective monobodies.
- This work paves the way for developing therapeutics against previously untargetable KRAS mutants.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Abnormal Proliferation

